InsidersTradesSigma
Track the Aldeyra Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Aldeyra Therapeutics, Inc. has recorded 39 insider filings. Market capitalisation: €105.6m. The latest transaction was filed on 5 June 2026 (Acquisition). Among the most active insiders: PERCEPTIVE ADVISORS LLC. Every trade is accessible without an account.
39
Insider Decl.
n/a
Thresholds
€22m
19 ops.
Buy Volume
€9m
10 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Aldeyra Therapeutics, Inc. Strong Buy (bullish), based on 6 analysts. Average price target: US$7.17.
47Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 June 2026
Declarations39 total
250,000 shares@ US$1.67380.34% mcap44.5% of flowCommon StockSEC:0001193125-26-259637:0
Canonical exit: 1 Sept 2026 (T+90)
70,000 shares@ US$1.40100.0% of flowCommon StockSEC:0001193125-26-117675:0
Canonical exit: 17 Jun 2026 (T+90)
5,000 shares@ US$1.42100.0% of flowCommon StockSEC:0001193125-26-116247:0
Canonical exit: 16 Jun 2026 (T+90)
2,500 shares@ US$5.3064.8% of flowCommon StockSEC:0000950170-25-109391:0
Canonical exit: 11 Nov 2025 (T+90)
22,073 shares@ US$5.151738.0% of flowCommon StockSEC:0000950170-25-108210:0
3,400,000 shares@ US$1.4210.5% of flowCommon StockSEC:0001062993-25-007163:0
413 shares@ US$12.81100.0% of flowCommon StockSEC:0000950170-24-116048:0
Canonical exit: 1 Aug 2021 (T+90)
10,834 shares@ US$4.736336.3% of flowCommon StockSEC:0000950170-24-097070:0
16,041 shares@ US$4.736343.5% of flowCommon StockSEC:0000950170-24-097071:0
13,201 shares@ US$3.406431.8% of flowCommon StockSEC:0000950170-24-045108:0
11,537 shares@ US$3.16420.9% of flowCommon StockSEC:0000950170-24-045113:0
140,281 shares@ US$4.671.4% of flowCommon StockSEC:0001062993-24-008171:0
Canonical exit: 3 Jul 2024 (T+90)
8,374 shares@ US$3.250.1% of flowCommon StockSEC:0001062993-24-007959:0
Canonical exit: 30 Jun 2024 (T+90)
13,201 shares@ US$3.406431.8% of flowCommon StockSEC:0000950170-24-030314:0
18,231 shares@ US$3.406435.6% of flowCommon StockSEC:0000950170-24-030311:0
97,914 shares@ US$3.273565.3% of flowCommon StockSEC:0000950170-24-030309:0
2,450,000 shares@ US$1.608.9% of flowCommon StockSEC:0001062993-23-019546:0
5,437 shares@ US$0.552100.0% of flowCommon StockSEC:0000950170-23-047497:0
192,084 shares@ US$0.55222.1% of flowCommon StockSEC:0000950170-23-047530:0
9,604 shares@ US$0.552100.0% of flowCommon StockSEC:0000950170-23-044379:0
9,604 shares@ US$0.552100.0% of flowCommon StockSEC:0000899243-23-016709:0
238,750 shares0Common StockSEC:0000899243-23-006742:0
100,000 shares@ US$7.501.8% of flowCommon StockSEC:0001062993-22-017733:0
Canonical exit: 7 Nov 2022 (T+90)
97,000 shares@ US$7.241.6% of flowCommon StockSEC:0001062993-22-017623:0
Canonical exit: 6 Nov 2022 (T+90)
141,000 shares@ US$6.952.3% of flowCommon StockSEC:0001062993-22-017559:0
Canonical exit: 3 Nov 2022 (T+90)
25 of 39 declarations
关于 Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc.（股票代码：ALDX）是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，在纳斯达克上市。该公司可追溯到 Aldexa Therapeutics，并于 2014 年更名为 Aldeyra Therapeutics。它作为一家临床阶段生物技术公司运营，专注于发现和开发免疫介导疾病的创新疗法。([ir.aldeyra.com](https://ir.aldeyra.com/faqs?utm_source=openai)) Aldeyra 的核心科学论点是其专有的 RASP 平台，该平台针对活性醛类物质，这是一类与炎症和疾病生物学相关的内源性分子。该平台旨在影响多种炎症途径，而不是依赖传统的单一蛋白质方法。这使得 Aldeyra 在小型生物技术公司中具有差异化定位，尽管投资案例仍然高度依赖临床验证和监管结果。([aldeyra.com](https://www.aldeyra.com/about/?utm_source=openai)) 该公司的主要资产是 reproxalap，一种正在开发用于干眼病体征和症状的试验性眼科溶液。该项目一直是股权故事的核心，也是波动性的来源：FDA 曾一度接受新药申请，于 2025 年 4 月发布了完整回复函，Aldeyra 随后于 2025 年 6 月重新提交了申请。2025 年 5 月，该公司还报告称，在一项 3 期干眼症室试验中达到了主要终点。后来的监管更新证实，FDA 接受了重新提交的审查，并指定了新的 PDUFA 目标行动日期。([sec.gov](https://www.sec.gov/Archives/edgar/data/1341235/000121390025064869/ea0249257-8k_aldeyra.htm?utm_source=openai)) 除了 reproxalap，Aldeyra 还在推进其他 RASP 调节剂，包括口服候选药物 ADX-629（正在研究用于全身性炎症疾病）和其他早期阶段项目。2025 年，该公司还强调将 RASP 平台扩展到中枢神经系统疾病，这表明其试图将产品线扩展到眼科以外，并进入其他炎症或免疫相关适应症。([ir.aldeyra.com](https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-advances-investigational-oral-rasp?utm_source=openai)) 从竞争角度来看，Aldeyra 在竞争激烈的生物技术领域运营，其中大型制药公司和资金更充足的同行主导着商业化和后期开发。其潜在优势在于 RASP 机制的新颖性以及创造同类首创或同类最佳资产的可能性。然而，该公司仍然是一家开发阶段的组织，面临着临床试验结果、FDA 决策、融资需求和未来商业化执行方面的重大风险。([aldeyra.com](https://www.aldeyra.com/science-technology/?utm_source=openai))
